ArticleCell & bioscience2025
Inhibition of miR-4284 could reduce apoptosis and neuroinflammation by targeting APBA1/JAK1/STAT3 signaling in Alzheimer's disease.
Article in Cell & bioscience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundmicroRNA-4284 is associated with various diseases, but its role in Alzheimer's disease remains unclear. This study explores the therapeutic potential of miR-4284 inhibition by targeting the APBA1 and the JAK/STAT3 pathways in AD models.
resultsmiR-4284 expression was analyzed in Aβ-treated SH-SY5Y cells and 5xFAD mice. Luciferase assays identified APBA1 as a direct target of miR-4284. Apoptosis, inflammation, and neuronal survival were assessed using qPCR, western blotting analysis, FACS, and immunohistochemistry. The Morris water maze test evaluated cognitive function, while western blotting analysis examined the JAK/STAT3 pathway. miR-4284 was upregulated in AD models. Its inhibition increased APBA1 expression, reduced Aβ accumulation, suppressed apoptosis and inflammation, and enhanced neuronal survival and cognitive function, correlating with JAK/STAT3 activation.
conclusionsmiR-4284 inhibition confers neuroprotection by modulating APBA1 and JAK/STAT3 signaling, suggesting its potential as a therapeutic target for AD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.